Business ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Obesity Treatments Weight Loss Drugs FDA Approval Eli Lilly Schizophrenia Treatments Obesity Drugs Combination Therapy CagriSema Gilead Sciences Phase I Trial Phase II Trial Weight Loss Treatments Market Analysis Liver Therapies Obexelimab Weight Loss Medications Synthetic Psilocybin Regulatory Approval Psychoactive Drugs RNA-based Therapies Efficacy Studies Bayer Zaltenibart Atezolizumab Anti-inflammatory Drugs Hemophilia Treatments Prostate Cancer Therapeutics Alzheimer's Disease Market Impact Hair Loss Treatments Acasunlimab Cancer Treatments

Genmab Halts Acasunlimab to Focus on Late-Stage Cancer Portfolio

The company is refocusing investment on late-stage drugs to pursue higher-impact opportunities.

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Multiple Firms File Securities Class Actions Against Telix in Indiana Federal Court Over Prostate Cancer Program Disclosures

ctDNA-Guided Atezolizumab Extends Survival After Bladder Cancer Surgery in Phase III Trial

Novo Nordisk Licenses Omeros’ MASP-3 Drug in Deal Worth Up to $2.1 Billion

Lilly Steps Up Obesity Push With San Diego Innovation Hub and $6.5 Billion Houston Factory

Eli Lilly Halts Diabetes Arm of Bimagrumab Obesity Trial Weeks After Launch

AbbVie Agrees to Buy Gilgamesh’s Bretisilocin for Up to $1.2 Billion